(Q46416681)

English

Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

0 references

positron emission tomography

1 reference

based on heuristic

inferred from title

author name string

G Moulin-Romsee

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

A Maes

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

D Silverman

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

L Mortelmans

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

K Van Laere

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

publication date

1 April 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

European Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

12

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

254-263

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology's practice parameters

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Early diagnosis of dementia: which tests are indicated? What are their costs?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Clinical-neuropathological correlations in Alzheimer's disease and related dementias

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Interpretation variability of 18FDG-positron emission tomography studies in dementia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Brain metabolic effects of Neotrofin in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Added Clinical Benefit of Incorporating 2-Deoxy-2-[F]Fluoro-D-Glucose with Positron Emission Tomography into the Clinical Evaluation of Patients with Cognitive Impairment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Multicenter clinicopathological correlation in dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.00940.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2004.00940.X

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15804241

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46416681&oldid=2110409366"